Application of Liquid Biopsy As Multi-functional Biomarkers in Head and Neck Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2021 Dec 8

PMID 34876674

Citations 22

Authors

Vasudha Mishra

Alka Singh

Xiangying Chen

Ari J Rosenberg

Alexander T Pearson

Alex Zhavoronkov

Peter A Savage

Mark W Lingen

Nishant Agrawal

Evgeny Izumchenko

Affiliations

Soon will be listed here.

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a molecularly heterogeneous disease, with a 5-year survival rate that still hovers at ~60% despite recent advancements. The advanced stage upon diagnosis, limited success with effective targeted therapy and lack of reliable biomarkers are among the key factors underlying the marginally improved survival rates over the decades. Prevention, early detection and biomarker-driven treatment adaptation are crucial for timely interventions and improved clinical outcomes. Liquid biopsy, analysis of tumour-specific biomarkers circulating in bodily fluids, is a rapidly evolving field that may play a striking role in optimising patient care. In recent years, significant progress has been made towards advancing liquid biopsies for non-invasive early cancer detection, prognosis, treatment adaptation, monitoring of residual disease and surveillance of recurrence. While these emerging technologies have immense potential to improve patient survival, numerous methodological and biological limitations must be overcome before their implementation into clinical practice. This review outlines the current state of knowledge on various types of liquid biopsies in HNSCC, and their potential applications for diagnosis, prognosis, grading treatment response and post-treatment surveillance. It also discusses challenges associated with the clinical applicability of liquid biopsies and prospects of the optimised approaches in the management of HNSCC.

Citing Articles

A scoping review of factors influencing the implementation of liquid biopsy for cancer care.

Sheriff S, Saba M, Patel R, Fisher G, Schroeder T, Arnolda G J Exp Clin Cancer Res. 2025; 44(1):50.

PMID: 39934875 PMC: 11817833. DOI: 10.1186/s13046-025-03322-w.

Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects.

Auger S, Mishra V, Singh A, Miao Y, Agrawal N, Izumchenko E Acad Oncol. 2025; 1(2).

PMID: 39867572 PMC: 11760339. DOI: 10.20935/acadonco7456.

Research progress of graphene-based nanomaterials in the diagnosis and treatment of head and neck cancer.

He J, Lin C, Hu Y, Gu S, Deng H, Shen Z Sci Prog. 2024; 107(4):368504241291342.

PMID: 39574301 PMC: 11585035. DOI: 10.1177/00368504241291342.

Artificial intelligence in fracture detection on radiographs: a literature review.

Lo Mastro A, Grassi E, Berritto D, Russo A, Reginelli A, Guerra E Jpn J Radiol. 2024; .

PMID: 39538068 DOI: 10.1007/s11604-024-01702-4.

Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges.

Li L, Sun Y MedComm (2020). 2024; 5(11):e766.

PMID: 39525954 PMC: 11550092. DOI: 10.1002/mco2.766.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Beynon R, Lang S, Schimansky S, Penfold C, Waylen A, Thomas S . Tobacco smoking and alcohol drinking at diagnosis of head and neck cancer and all-cause mortality: Results from head and neck 5000, a prospective observational cohort of people with head and neck cancer. Int J Cancer. 2018; 143(5):1114-1127. PMC: 6099366. DOI: 10.1002/ijc.31416. View

Johnson D, Burtness B, Leemans C, Lui V, Bauman J, Grandis J . Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6(1):92. PMC: 7944998. DOI: 10.1038/s41572-020-00224-3. View

Elrefaey S, Massaro M, Chiocca S, Chiesa F, Ansarin M . HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2015; 34(5):299-309. PMC: 4299160. View

Bonner J, Harari P, Giralt J, Azarnia N, Shin D, Cohen R . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78. DOI: 10.1056/NEJMoa053422. View

Astsaturov I, Cohen R, Harari P . EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2006; 6(8):691-710. DOI: 10.2174/156800906779010191. View

Leemans C, Braakhuis B, Brakenhoff R . The molecular biology of head and neck cancer. Nat Rev Cancer. 2010; 11(1):9-22. DOI: 10.1038/nrc2982. View

Shanmugam A, Hariharan A, Hasina R, Nair J, Katragadda S, Irusappan S . Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma. Cancer. 2021; 127(10):1576-1589. PMC: 8084899. DOI: 10.1002/cncr.33393. View

Soda N, Rehm B, Sonar P, Nguyen N, Shiddiky M . Advanced liquid biopsy technologies for circulating biomarker detection. J Mater Chem B. 2019; 7(43):6670-6704. DOI: 10.1039/c9tb01490j. View

10.

Egyud M, Sridhar P, Devaiah A, Yamada E, Saunders S, Stahlberg A . Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer. Head Neck. 2018; 41(5):1351-1358. PMC: 6467749. DOI: 10.1002/hed.25563. View

11.

Wang Y, Springer S, Mulvey C, Silliman N, Schaefer J, Sausen M . Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015; 7(293):293ra104. PMC: 4587492. DOI: 10.1126/scitranslmed.aaa8507. View

12.

Agrawal N, Frederick M, Pickering C, Bettegowda C, Chang K, Li R . Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333(6046):1154-7. PMC: 3162986. DOI: 10.1126/science.1206923. View

13.

Stransky N, Egloff A, Tward A, Kostic A, Cibulskis K, Sivachenko A . The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333(6046):1157-60. PMC: 3415217. DOI: 10.1126/science.1208130. View

14.

Boyle J, Mao L, Brennan J, Koch W, Eisele D, Saunders J . Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg. 1994; 168(5):429-32. DOI: 10.1016/s0002-9610(05)80092-3. View

15.

Pall A, Jakobsen K, Gronhoj C, von Buchwald C . Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review. Acta Oncol. 2020; 59(7):845-850. DOI: 10.1080/0284186X.2020.1742930. View

16.

Liu M, Oxnard G, Klein E, Swanton C, Seiden M . Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2021; 31(6):745-759. PMC: 8274402. DOI: 10.1016/j.annonc.2020.02.011. View

17.

Lim Y, Wan Y, Vagenas D, Ovchinnikov D, Perry C, Davis M . Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers. BMC Cancer. 2016; 16(1):749. PMC: 5034533. DOI: 10.1186/s12885-016-2785-0. View

18.

Rapado-Gonzalez O, Martinez-Reglero C, Salgado-Barreira A, Muinelo-Romay L, Muinelo-Lorenzo J, Lopez-Lopez R . Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part I: A Diagnostic Accuracy Meta-Analysis. J Pers Med. 2021; 11(6). PMC: 8233749. DOI: 10.3390/jpm11060568. View

19.

Schrock A, Leisse A, de Vos L, Gevensleben H, Droge F, Franzen A . Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. Clin Chem. 2017; 63(7):1288-1296. DOI: 10.1373/clinchem.2016.270207. View

20.

Langevin S, Koestler D, Christensen B, Butler R, Wiencke J, Nelson H . Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study. Epigenetics. 2012; 7(3):291-9. PMC: 3335952. DOI: 10.4161/epi.7.3.19134. View